Last reviewed · How we verify

Switch to DTG + 3TC — Competitive Intelligence Brief

Switch to DTG + 3TC (Switch to DTG + 3TC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (INSTI + NRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination (INSTI + NRTI) HIV integrase; HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Switch to DTG + 3TC (Switch to DTG + 3TC) — Hospitales Universitarios Virgen del Rocío. DTG (dolutegravir) inhibits HIV integrase to prevent viral DNA integration into the host genome, while 3TC (lamivudine) inhibits reverse transcriptase to block HIV replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Switch to DTG + 3TC TARGET Switch to DTG + 3TC Hospitales Universitarios Virgen del Rocío marketed Antiretroviral combination (INSTI + NRTI) HIV integrase; HIV reverse transcriptase
Dolutegravir/Lamivudine as a single pill Dolutegravir/Lamivudine as a single pill Fundacion SEIMC-GESIDA marketed Antiretroviral combination (INSTI + NRTI) HIV integrase; HIV reverse transcriptase
Sofosbuvir, Ribavirin, and Stribild Sofosbuvir, Ribavirin, and Stribild Saint Michael's Medical Center marketed Direct-acting antiviral (DAA) combination; antiretroviral combination HCV NS5B RNA polymerase; HIV integrase; HIV reverse transcriptase
Dolutegravir / Lamivudine Pill Dolutegravir / Lamivudine Pill Charlotte-Paige Rolle, MD marketed Antiretroviral combination (INSTI + NRTI) HIV integrase; HIV reverse transcriptase
Raltegravir; Abacavir/Lamivudine Raltegravir; Abacavir/Lamivudine Central Institute of Epidemiology, Moscow, Russia marketed Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) HIV integrase; HIV reverse transcriptase
Raltegravir and truvada Raltegravir and truvada The University of Texas Health Science Center, Houston marketed Antiretroviral combination (INSTI + NRTI) HIV integrase; HIV reverse transcriptase
DTG/3TC DTG/3TC University of Nairobi marketed Antiretroviral combination (integrase strand transfer inhibitor + nucleoside reverse transcriptase inhibitor) HIV integrase; HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (INSTI + NRTI) class)

  1. ViiV Healthcare · 2 drugs in this class
  2. Denver Infectious Disease Consultants, PLLC · 1 drug in this class
  3. Fundacion SEIMC-GESIDA · 1 drug in this class
  4. Fundação Bahiana de Infectologia · 1 drug in this class
  5. Charlotte-Paige Rolle, MD · 1 drug in this class
  6. Saint Michael's Medical Center · 1 drug in this class
  7. The University of Texas Health Science Center, Houston · 1 drug in this class
  8. Hospitales Universitarios Virgen del Rocío · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Switch to DTG + 3TC — Competitive Intelligence Brief. https://druglandscape.com/ci/switch-to-dtg-3tc. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: